Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: DMRA) | Delayed: 21.60 +0.11 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.49 | 52 Week High | $ | |||
| Open | $21.75 | 52 Week Low | $ | |||
| Day High | $21.94 | P/E | N/A | |||
| Day Low | $20.75 | EPS | $ | |||
| Volume | 497,326 | |||||
